SCHEMBL55983

SCHEMBL55983

CN1CCN(Cc2ccc(N)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 1.00
ALDH1A1 P00352 3/20 0.66
MC4R P32245 1/20 0.66
CHKA P35790 6/20 0.64
CA2 P00918 1/20 0.64
NCF1 P14598 1/20 0.64
PRMT6 Q96LA8 1/20 0.64
HDAC6 Q9UBN7 1/20 0.54
KDM4E B2RXH2 2/20 0.53
NPC1 O15118 2/20 0.53
TP53 P04637 2/20 0.53
RAB9A P51151 2/20 0.53
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
ADRA2C P18825 1/20 0.52
GFER P55789 1/20 0.52
KMT2A Q03164 1/20 0.52
PTK2B Q14289 1/20 0.52
ESR2 Q92731 1/20 0.52
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1675964 0.98 LMNA (0.96) LMNAALDH1A1MC4RCHKACA2
SCHEMBL12834843 0.93 LMNA (0.86) LMNAALDH1A1MC4RCHKACA2
SCHEMBL10690328 0.89 LMNA (0.80) LMNAALDH1A1MC4RCHKACA2
SCHEMBL22802858 0.85 LMNA (0.73) LMNAALDH1A1MC4RCHKACA2
SCHEMBL5912658 0.85 LMNA (0.73) LMNAALDH1A1MC4RCHKACA2
SCHEMBL2481337 0.84 LMNA (0.71) LMNAALDH1A1KDM4ENPC1RAB9A
SCHEMBL374400 0.84 LMNA (0.72) LMNAALDH1A1CHKACA2NCF1
SCHEMBL111367 0.84 CHKA (0.86) LMNAALDH1A1MC4RCHKACA2
SCHEMBL15652459 0.84 LMNA (0.71) LMNAALDH1A1MC4RCHKACA2
Hydrochloric Acid SCHEMBL3868716 0.83 LMNA (0.71) LMNAALDH1A1MC4RCHKACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2012-05-17 US claimed
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers NOVARTIS AG (CH) 2010-02-04 US claimed
US-7579356-B2 Thia-tetraazaacenaphthylene kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-08-25 US claimed
EP-1996558-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 EP claimed
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 US claimed
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-15 US claimed
WO-2007104538-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2007-09-20 WO claimed
US-12637463-B2 Tricyclic kinase inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 US disclosed
US-20260103455-A1 ULK3 INHIBITORS AND USES THEREOF H LEE MOFFITT CANCER CT & RES (US) 2026-04-16 US disclosed
US-20260078126-A1 BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2026-03-19 US disclosed
WO-2025231152-A1 COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION THE CLEVELAND CLINIC FOUNDATION (US) 2025-11-06 WO disclosed
US-20250282736-A1 SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR ST JUDE CHILDRENS RES HOSPITAL (US) 2025-09-11 US disclosed
US-12398145-B2 Bicyclic urea kinase inhibitors and uses thereof THE BROAD INSTITUTE, INC. (US) 2025-08-26 US disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 WO disclosed
CN-1391557-A 6-substituted indolinones, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA (DE) 2003-01-15 CN disclosed
EP-1224170-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim Pharma KG (DE) 2002-07-24 EP disclosed
WO-2002036564-A1 SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-05-10 WO disclosed
WO-2001027081-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-19 WO disclosed
US-4140775-A HYPOTENSIVE AGENTS THE UPJOHN COMPANY (US) 1979-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers SLC8B1, MCU, GLS LMNA 2752/4885ALDH1A1 2955/4885MC4R 3574/4885
US-12637463-B2 Tricyclic kinase inhibitors and uses thereof CDK1, CDK11A, CDK11B LMNA 935/4885ALDH1A1 2753/4885MC4R 1531/4885
US-20260078126-A1 BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF SIK2, SBK3, SIK3 LMNA 997/4885ALDH1A1 4254/4885MC4R 3849/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C LMNA 1653/4885ALDH1A1 2487/4885MC4R 2146/4885
US-12398145-B2 Bicyclic urea kinase inhibitors and uses thereof SIK1, SIK2, SIK3 LMNA 1719/4885ALDH1A1 3729/4885MC4R 4659/4885
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide ADK, MAP3K9, MAP4K5 LMNA 3244/4885ALDH1A1 924/4885MC4R 2809/4885
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS MAP4K2, MAP3K6, MAP3K2 LMNA 4421/4885ALDH1A1 1988/4885MC4R 2634/4885
US-20250282736-A1 SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR NR1H4, NR1I2, NR1I3 LMNA 4827/4885ALDH1A1 3469/4885MC4R 583/4885
US-20260103455-A1 ULK3 INHIBITORS AND USES THEREOF ULK3, ULK1, ULK2 LMNA 1991/4885ALDH1A1 3985/4885MC4R 3685/4885
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES MAP3K20, PHKG1, PHKG2 LMNA 2458/4885ALDH1A1 4102/4885MC4R 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.